Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
A/T/S vs ANDROID 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
A/T/S (erythromycin) is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Treatment of acne vulgaris (FDA-approved indication),Treatment of bacterial infections caused by susceptible organisms (off-label use for acne is the primary use)
Testosterone replacement therapy for male hypogonadism,Off-label: delayed puberty in males
Dosing is individualized based on antithrombin activity level. For acute thrombotic events: initial bolus of 30-50 IU/kg followed by maintenance dosing to achieve target activity levels (80-120% of normal). Prophylaxis: 40-60 IU/kg every 24 hours.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
Terminal elimination half-life: 1–2 hours (prolonged in hepatic impairment).
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Antithrombin is a glycoprotein; its metabolism involves cellular uptake and catabolism, but specific CYP450 enzymes are not involved. Degradation occurs via proteolysis and reticuloendothelial system clearance.
Hepatic via CYP3A4 and CYP2B6; undergoes first-pass metabolism.
Renal: 10-20% (active drug and metabolites); Fecal: minimal; Biliary: not significant.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
70-90% bound to serum albumin.
98% bound to sex hormone-binding globulin (SHBG) and albumin.
0.5–0.8 L/kg (low Vd, minimal tissue penetration).
Vd approximately 1.0 L/kg; indicates extensive tissue distribution, especially to reproductive organs and bone marrow.
Topical: 1–5% (minimal systemic absorption).
Oral: 15–25% due to first-pass metabolism; buccal or transdermal: higher, but not commercially available for this formulation.
No specific adjustment required; drug is not renally eliminated.
No specific dose adjustment required based on GFR; caution in severe impairment (Cr Cl <30 m L/min) due to potential fluid retention.
No specific adjustment; antithrombin is produced in the liver, but exogenous replacement does not require dose adjustment in hepatic impairment.
Contraindicated in Child-Pugh class B and C cirrhosis due to hepatotoxicity risk; in class A, use with caution and monitor liver function.
Dosing based on weight and antithrombin levels; typical initial dose 30-50 IU/kg, followed by maintenance to achieve target levels. Clinical trial data limited in neonates.
Not recommended for use in children as it may cause premature epiphyseal closure and virilization; limited data.
No specific adjustment; use standard dosing with monitoring of antithrombin activity and bleeding risk.
Increased risk of prostatic hyperplasia and carcinoma; use lowest effective dose with regular prostate monitoring.
None.
Warning: Prolonged use may cause virilization in women, premature epiphyseal closure, and increased risk of prostatic hypertrophy/carcinoma.
Hypersensitivity reactions including anaphylaxis have occurred.,Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Use with caution in patients with hepatic impairment.,Potential for QT prolongation and ventricular arrhythmias, especially with intravenous administration or concomitant drugs that prolong QT interval.
Monitor liver function, lipid profile, and prostate-specific antigen; risk of edema in patients with cardiac disease; avoid use in patients with sleep apnea.
Hypersensitivity to erythromycin or any macrolide antibiotic.,Use with caution in patients with pre-existing QT prolongation or electrolyte abnormalities (relative contraindication).
Known or suspected prostate cancer; breast cancer in males; hypersensitivity to androgens; pregnancy and lactation.
No specific food interactions. Avoid excessive alcohol consumption as it may increase skin dryness.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit salt intake to reduce fluid retention. Alcohol may increase risk of liver toxicity.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. Topical erythromycin has minimal systemic absorption; risk to fetus is low across all trimesters.
Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial fusion. Risk is highest during first trimester but applies throughout gestation.
Compatible with breastfeeding. Erythromycin is excreted into breast milk in small amounts (M/P ratio approximately 0.5). Topical use results in negligible systemic exposure; unlikely to cause adverse effects in nursing infants.
Excretion into human milk is unknown. Due to potential for androgenic effects in nursing infants, breastfeeding is not recommended. No M/P ratio available.
No dose adjustment required. Systemic absorption from topical application is minimal and not significantly altered by pregnancy-related pharmacokinetic changes.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist for pregnant patients.
A/T/S (erythromycin 2% topical solution) is indicated for acne vulgaris. Avoid contact with eyes, mouth, and mucous membranes. May cause skin dryness or irritation; use moisturizer. Effectiveness may decrease with prolonged use due to bacterial resistance. Not recommended for use with other topical erythromycin products or clindamycin to avoid antagonism.
Android 5 (methyltestosterone) is an androgenic anabolic steroid used for hypogonadism and delayed puberty. Monitor liver function due to hepatotoxicity. Use with caution in elderly due to increased risk of prostatic hypertrophy and carcinoma. Can cause fluid retention in patients with cardiac, renal, or hepatic disease. Avoid in patients with breast cancer or known or suspected prostate cancer.
Apply a thin layer to affected areas twice daily after washing.,Avoid contact with eyes, lips, and mouth; if contact occurs, rinse thoroughly with water.,May cause stinging, burning, or peeling; if irritation persists, consult your doctor.,Use sunscreen daily as this medication may increase sensitivity to sunlight.,Do not use more than prescribed; overuse may increase side effects without improving results.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Keep away from open flames or heat sources; product is flammable.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe stomach pain.,Women should report any signs of virilization: hoarseness, acne, menstrual changes, growth of facial hair.,Men should report any breast enlargement, changes in urination, or priapism.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Do not use if you are pregnant or planning to become pregnant.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about A/T/S vs ANDROID 5, answered by our medical review team.
A/T/S is a Macrolide antibiotic that works by A/T/S (erythromycin) is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.. ANDROID 5 is a Androgen that works by Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between A/T/S and ANDROID 5 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of A/T/S is: Dosing is individualized based on antithrombin activity level. For acute thrombotic events: initial bolus of 30-50 IU/kg followed by maintenance dosing to achieve target activity levels (80-120% of normal). Prophylaxis: 40-60 IU/kg every 24 hours.. The standard adult dose of ANDROID 5 is: 2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between A/T/S and ANDROID 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. A/T/S is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. Topical erythromycin has minimal systemic absorption; risk . ANDROID 5 is classified as Category C. Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.